Cardiovascular safety of linagliptin in type 2 diabetes: a comprehensive patient-level pooled analysis of prospectively adjudicated cardiovascular events

@inproceedings{Rosenstock2015CardiovascularSO,
  title={Cardiovascular safety of linagliptin in type 2 diabetes: a comprehensive patient-level pooled analysis of prospectively adjudicated cardiovascular events},
  author={Julio Rosenstock and Nikolaus Marx and Dietmar Neubacher and Thomas L Seck and Sanjay R. Patel and H. W{\"o}rle and Odd Erik Johansen},
  booktitle={Cardiovascular Diabetology},
  year={2015}
}
BackgroundThe cardiovascular (CV) safety of linagliptin was evaluated in subjects with type 2 diabetes (T2DM).MethodsPre-specified patient-level pooled analysis of all available double-blind, randomized, controlled trials, ≥12 weeks’ duration (19 trials, 9459 subjects) of linagliptin versus placebo/active treatment. Primary end point: composite of prospectively adjudicated CV death, non-fatal myocardial infarction, non-fatal stroke, and hospitalization for unstable angina (4P-MACE… CONTINUE READING

Citations

Publications citing this paper.
SHOWING 1-10 OF 41 CITATIONS

Saudi Heart Association (SHA) guidelines for the management of heart failure

  • Journal of the Saudi Heart Association
  • 2019
VIEW 1 EXCERPT
CITES BACKGROUND

References

Publications referenced by this paper.
SHOWING 1-10 OF 49 REFERENCES

Alogliptin after acute coronary syndrome in patients with type 2 diabetes.

  • The New England journal of medicine
  • 2013
VIEW 4 EXCERPTS
HIGHLY INFLUENTIAL

Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes mellitus.

  • The New England journal of medicine
  • 2013
VIEW 5 EXCERPTS
HIGHLY INFLUENTIAL

Results from EXAMINE

W. White
  • Oral presentation at EASD 2013. http:// www.cardiotimes.com/documents/powerpoints/SLI064.ppt. Accessed May
  • 2015
VIEW 2 EXCERPTS